Clinical observation of pancreaticoduodenectomy combined with tegafur/gimeracil/oteracil (S-1) adjuvant chemotherapy for pancreatic cancer
Author:
Affiliation:

Clc Number:

R735.9

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    Objective: To assess the efficacy of pancreaticoduodenectomy (PD) followed by tegafur/gimeracil/oteracil (S-1) adjuvant chemotherapy in treatment of pancreatic cancer. Methods: Between February 2008 and June 2011, 58 patients with stage I-II pancreatic cancer underwent PD followed by postoperative adjuvant chemotherapy with S-1 (32 cases, observational group) or gemcitabine (26 cases, control group). The short- and long- term efficacies as well as the incidence of adverse events during chemotherapy between the two groups of patients were compared. Results: The levels of serum tumor markers in both groups of patients were significantly decreased after chemotherapy compared with their levels before chemotherapy (all P<0.05), but showed no significant difference between the two groups (all P>0.05); the overall response rate in observational group was significantly higher than that in control group (37.50% vs. 30.77%, P<0.05); survival analysis showed that the 1-, 1.5- and 2-year overall survival rate in observational group were significantly higher than those in control group (all P<0.05); the adverse reactions in either group were grade I or II, and there was no significant difference in incidence of adverse reactions between the two groups (P>0.05). Conclusion: PD plus postoperative S-1 adjuvant chemotherapy for pancreatic cancer patients has proven efficacy, which may effectively prolong the postoperative survival time of the patients, with only mild adverse effects, and good tolerance.

    Reference
    Related
    Cited by
Get Citation

LI Hongbo, LIU Chongzhou. Clinical observation of pancreaticoduodenectomy combined with tegafur/gimeracil/oteracil (S-1) adjuvant chemotherapy for pancreatic cancer[J]. Chin J Gen Surg,2015,24(9):1232-1236.
DOI:10.3978/j. issn.1005-6947.2015.09.005

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:June 09,2015
  • Revised:August 16,2015
  • Adopted:
  • Online: September 15,2015
  • Published: